Genmab A/S logo

GMAB

Genmab A/S

$47.06

Earnings Summary

Revenue
$2961.23Mn
Net Profits
$1471.86Mn
Net Profit Margins
49.7%

Highlights

Revenue:

Genmab A/S’s revenue jumped 139.61% since last year same period to $2961.23Mn in the Q4 2019. On a quarterly growth basis, Genmab A/S has generated 184.78% jump in its revenue since last 3-months.

Net Profits:

Genmab A/S’s net profit jumped 76.51% since last year same period to $1471.86Mn in the Q4 2019. On a quarterly growth basis, Genmab A/S has generated 174.07% jump in its net profits since last 3-months.

Net Profit Margins:

Genmab A/S’s net profit margin fell -26.33% since last year same period to 49.7% in the Q4 2019. On a quarterly growth basis, Genmab A/S has generated -3.76% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Genmab A/S post its latest quarter earnings

EPS Estimate Current Quarter
0.27
EPS Estimate Current Year
0.27

Highlights

EPS Estimate Current Quarter:

Genmab A/S’s earning per share (EPS) estimates for the current quarter stand at 0.27 - a 17.31% jump from last quarter’s estimates.

EPS Estimate Current Year:

Genmab A/S’s earning per share (EPS) estimates for the current year stand at 0.27.

Key Ratios

Key ratios of the Genmab A/S post its Q4 2022 earnings

Earning Per Share (EPS)
0

Highlights

Earning Per Share (EPS):

Genmab A/S’s earning per share (EPS) fell -100% since last year same period to 0 in the Q4 2022. This indicates that the Genmab A/S has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-03-31
0.08
0.1
24.62%
2023-02-22
0.27
0
-100%
2022-06-30
0.19
0.4
105.25%

Company Information

Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund.

Organisation
Genmab A/S
Headquarters
Kalvebod Brygge 43, Copenhagen, Denmark, 1560
Employees
1560
Industry
Health Technology
CEO
Jan van de Winkel

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*